Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03361423 · ClinicalTrials.gov registry record · NA

Evaluation of a Novel Device for Treatment of Migraine Headache

A NA study, sponsored by Theranica.

Completed
Registry status
NA
Development phase
296
Enrollment target

NCT03361423 is a NA study that has completed, run by Theranica. The registered enrollment target is 296 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03361423, a NA study, has completed, sponsored by Theranica.

COMPLETED
Registry status
NA
Development phase
296 participants
Enrollment target

Study Summary

Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment. Recent evidence suggests that electro stimulation is effective in providing relief for chronic headaches including migraine. It is tolerable by patients and associated with no adverse effects. The device utilizes electro stimulation to achieve conditioned pain modulation (CPM). CPM an stimulate endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere. This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications. The study objectives is to demonstrate the safety and effectiveness of the Nerivio Migra electro stimulation device for the reduction of migraine headache during an attack of migraine with or without aura. The study is intended for subject with 2-8 migraine episodes per month. patients will receive the device, either an active or a placebo type, and will be asked to use the device at home or in any location that they will be when the migraine starts. The study hypothesis is that electro stimulation delivered transcutaneously to the peripheral nervous system at onset of a migraine attack significantly reduce headache pain demonstrated by a significant difference between proportions of responders to the active treatment stimulation in comparison to proportion of responders that will use a placebo device.

Interventions

  • DEVICE Nerivio Migra-1 active device
  • DEVICE Nerivio Migra-1 Sham device

Trial Details

FieldValue
Enrollment Target 296 participants
Start Date 2017-12-17
Est. Completion 2018-12-25
Phase NA

Sponsor

Theranica

22 total trials

What the Registry Record Tells You About NCT03361423

The ClinicalTrials.gov registry entry for NCT03361423 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Nerivio Migra-1 active device is the first listed.

NCT03361423 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03361423 about?

NCT03361423 is a clinical study titled "Evaluation of a Novel Device for Treatment of Migraine Headache". Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment. Recent evidence suggests that electro stimulation is effective in providing relief for chronic headaches includin...

What is the current status of trial NCT03361423?

This trial is currently completed. It is a NA study. The enrollment target is 296 participants. The study started on 2017-12-17. Estimated completion is 2018-12-25.

What interventions are being tested in trial NCT03361423?

The interventions under investigation include: Nerivio Migra-1 active device (DEVICE), Nerivio Migra-1 Sham device (DEVICE).

Who is sponsoring clinical trial NCT03361423?

This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.